MTCYBP22

Across TCGA pan-cancer cohorts, MTCYBP22 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MTCYBP22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MTCYBP22 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCYBP22 is over-expressed in tumor, although a few such as KIRC and STAD show the opposite, repressed pattern.

KIRC and STAD are the cancer types where MTCYBP22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCYBP22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	−0.109	.031	3	view →
STAD	All	II,III,IV	−0.287	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

MTCYBP22–KIRC

Open the KIRC breakdown →